Biotechnology

World-first predictive test for Diabetic Kidney Disease could save $384 billion over 10 years

* Independent modelling estimates the PromarkerD predictive test for diabetic kidney disease (DKD) would increase the quality of care and could save US payers almostUSD400 billion over 10 years * The US is home to 31 million adults with diabetes who are at risk of DKD - cost savings stem from...

2021-06-25 23:30 3181

Vazyme Brings COVID-19 Testing Solutions at Medlab 2021

DUBAI, UAE, June 25, 2021 /PRNewswire/ -- Chinese biotechnology company Nanjing Vazyme Biotech Co., Ltd (Vazyme) showcased its lineup of COVID-19 testing solutions and its point-of-care testing (POCT) in vitro diagnostic instruments at the 2021 Medlab Middle East, an industry-leading medical labo...

2021-06-25 15:31 1957

Research showed that InxMed FAK Inhibitor (IN10018) Overcomes Drug Resistance of KRAS G12C inhibitors and Synergizes with KRAS G12C inhibitors in Treating Cancer

SHANGHAI, June 25, 2021 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today one study in collaboration with Ruijin Hospital, Shanghai Jiaotong ...

2021-06-25 15:06 1908

Samsung Biologics Issues Its First Annual Sustainability Report

* Consolidation of the company's roadmap to creating an improved business environment * Establishment of an ESG Committee for its continued efforts for environmental performance * Showcases the company's long-term commitment to social responsibility as part of its mission to build a bett...

2021-06-25 09:01 23337

TCI JAPAN Launched its Breakthrough, SCIENCE OF PROBIOTICS, Demonstrating How to Keep Probiotics Alive without Refrigeration for over 1 year

TAIPEI, June 24, 2021 /PRNewswire/ -- To keep enough probiotics alive in products, sellers and consumers must meet the storage conditions, especially storagetemperature. Since most live probiotics can only survive in a low-temperature environment, most probiotic products, especially lactic acid ...

2021-06-25 09:00 2533

Over a year into the global pandemic, Samsung Biologics continues to leverage innovative virtual platform for remote audits and regulatory inspections

* Samsung Biologics' Live Virtual Tour (LVT) used in one of the earliest FDA full virtual assessments * Recently hosted EMA for 6 PAIs simultaneously using LVT INCHEON, South Korea ,June 23, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (C...

2021-06-23 19:28 1962

100 Billion Live Probiotics in a Bottle: TCI JAPAN Launched its Breakthrough, SCIENCE OF PROBIOTICS, After 20 Years of Research

TAIPEI, June 23, 2021 /PRNewswire/ -- Probiotic drinks now available on the market often cannot fully exert the effect despite the content of lactic acid bacteria because live bacteria in thedrinks can be killed over time or due to poor storage, which causes the numbers of live probiotics consume...

2021-06-23 14:28 2297

Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars

BEIJING and BOSTON, June 22, 2021 /PRNewswire/ -- Biocytogen, an international biotechnology company focused on antibody drug research and development (R&D) using innovative genetically engineered animal models, today announced the successful completion of a new round of financing totaling tens o...

2021-06-23 04:16 2058

Phase III Clinical Trial of BIOKANGTAI COVID-19 Vaccine Initiated in Malaysia

SHENZHEN, China, June 22, 2021 /PRNewswire/ -- On June 21, local time, phase III clinical fieldwork of the Inactivated COVID-19 Vaccine (Vero cells) independently developed and manufactured by Shenzhen Kangtai Biological Products Co., Ltd. was officially initiated inMalaysia, and the first batch ...

2021-06-22 22:32 10212

Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.

NANJING, China, June 20, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL...

2021-06-20 21:00 3459

InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma

BEIJING, June 18, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib atthe 16th International Conf...

2021-06-18 17:12 14385

Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study. This study will eval...

2021-06-17 15:41 14536

InnoCare Announces Orphan Drug Designation of Gunagrabtinib by US FDA for Treatment of Cholangiocarcinoma

BEIJING, June 16, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its pan-FGFR inhibitor gunagratinib (ICP-192) ...

2021-06-17 11:31 14811

Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer t...

2021-06-16 13:08 9111

Totient, a Viva Biotech Portfolio Company, has been Acquired by AbSci

SHANGHAI, June 15, 2021 /PRNewswire/ -- Viva Biotech (01873.HK) declared today that Totient, one of its portfolio companies, has been acquired by AbSci, a synthetic biology company unlocking the potential of proteins as next-generation therapeutics. Totient is a biotech company, harnessing human ...

2021-06-16 10:14 23511

BIO Digital Taiwan Day will be held on June 22

TAIPEI, June 15, 2021 /PRNewswire/ -- With COVID-19 dramatically changing the healthcare industry, organizations have been forced to adapt their practices and embrace digital transformation - and now, as vaccines become more available in the developed countries, it is time to look into the future...

2021-06-15 23:00 2899

The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients

SHANGHAI, June 14, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients wit...

2021-06-15 08:46 1668

Happiness Biotech Signed Agreement To Distribute Volkswagen Electric Vehicles

NANPING, China, June 14, 2021 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer and e-commerce services provider, announced today that Taochejun (Fujian) Automobile Distribution Co., Ltd. ("Taoc...

2021-06-14 20:00 11573

Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis

SEONGNAM, South Korea, June 13, 2021 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) announced today the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293). Th...

2021-06-14 06:00 2647

OliPass Expands Scientific Advisory Board by Inviting Experts in Pain To Bolster Phase 2 Clinical Trial Design and Management

SEOUL, South Korea, June 10, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced that it is expanding its Scientific Advisory Board ("SAB") for SCN9A antisense pain killer OLP-1002 to include ProfessorPatrick M. Do...

2021-06-10 21:00 1872
1 ... 160161162163164